Table 1.
Comparison of demographic features, disability on admission, and laboratory and instrumental examinations performed in GBS hospitalized in February 2019–2020 vs March 2020–2021.
| GBS February 2019–2020 n = 14 |
GBS March 2020–2021 n = 20 |
Value*,† | P | |
|---|---|---|---|---|
| Age (mean ± SD) | 58 ± 16.7 | 64.5 ± 10.72 | −2,99† | .17 |
| M:F | 11:3 | 11:9 | 2004* | .147 |
| MRC score | 45.5 ± 13.6 | 41.7 ± 15.27 | 0.043† | .462 |
| Hughes score on admission | ||||
| 1 | 2 | 1 | 5.714 | 0.032 |
| 2 | 8 | 5 | ||
| 3 | 1 | 4 | ||
| 4 | 3 | 10 | ||
| GBS subtypes | ||||
| AIDP | 7/14 | 7/10 GBS+, 6/10 GBS-C− | ||
| AMAN/AMSAN | 4/14 | 2/10 GBS+, 3/10 GBS-C− | ||
| Other | 3/14 (Miller-Fisher: 2, pharingo-cervico-brachial: 1) | 1/10 GBS+ (Miller-Fisher), 1/10 GBS-C− (Miller-Fisher) | ||
| Facial involvement | 2/14 | 7/20 | 2.045* | .360 |
| Antiganglioside antibodies | Not searched: 6/14 | Not searched: 3/20 (all GBS-C+) | ||
| Negative: 5 | Negative: 10/10 GBS-C+, 6/10 GBS-C− | |||
| Positive: 3 (GM1, GQ1b, MOG) | Positive: 1 GBS-C− (GQ1b) | |||
| Imaging examination | ||||
| Brain MRI | 4/10 (28%) | 5/20 (25%), 1/10 GBS-C+, 4/10 GBS-C− | ||
| Spinal MRI | 10/14 (71%) | 14/20 (70%), 4/10 GBS-C+, 10/10 GBS-C− | ||
| EMG examination | 14 | 20 | ||
| CSF examination | 14 | 20 | ||